Can People Get Heartworms From Dogs? Transmission, Risks, and Rare Cases

Can people get heartworms from dogs? Human infection with Dirofilaria immitis is extremely rare but documented. The parasite cannot complete its life cycle in humans, so an infected dog cannot transmit heartworms to a person through casual contact. Transmission requires a mosquito vector, and even then, the worms almost never reach the human heart. Instead, they typically die in the lungs, forming benign nodules that mimic cancer on imaging. There is no direct dog-to-human transmission path, and no treatment is usually needed for humans.

The fear is understandable. A dog coughing on the couch, a positive heartworm test, and suddenly every family member wonders about their own risk. The anxiety is amplified by the severity of heartworm disease in dogs, which can be fatal if untreated. But the biology tells a reassuring story, one grounded in decades of veterinary and medical surveillance. Understanding the actual transmission chain, the dead-end nature of human infection, and the specific conditions required for any human case to occur transforms vague fear into precise knowledge.

The mechanism: why heartworms need mosquitoes, not contact

Heartworm disease is caused by Dirofilaria immitis, a filarial nematode. The parasite's life cycle is obligate, meaning it cannot skip steps. Adult worms live in the pulmonary arteries of infected dogs, where females release microscopic offspring called microfilariae. These microfilariae circulate in the dog's blood but cannot develop further unless a female mosquito ingests them during a blood meal.

Inside the mosquito, microfilariae molt twice over 10 to 14 days, becoming infective third-stage larvae. When the mosquito bites another dog, these larvae enter the new host and migrate through subcutaneous tissue for roughly 70 to 90 days. They then enter the bloodstream and reach the pulmonary arteries, where they mature into adults over 6 to 7 months. Adult worms can live 5 to 7 years in dogs, producing microfilariae that perpetuate the cycle.

This mechanism explains the first barrier to human infection. A person cannot acquire heartworms by touching an infected dog, cleaning up its waste, or breathing the same air. The microfilariae are not shed in feces, urine, or saliva. They exist in the bloodstream and are accessible only to a blood-feeding mosquito. Without that mosquito bite, there is no transmission.

In plain terms: the dog is a reservoir, the mosquito is the syringe, and the human is an accidental recipient who cannot pass the parasite onward.

How often do human heartworm infections actually occur?

Quantifying human risk is difficult because most cases are asymptomatic and discovered incidentally. But the available data paint a picture of extreme rarity. The Centers for Disease Control and Prevention documented 56 human cases of Dirofilaria immitis infection in the United States between 1965 and 2013. That averages fewer than one case per year nationwide. For context, dogs in the United States test positive for heartworms at a rate of roughly 1 in 100, with higher prevalence in the Southeast and along the Mississippi River.

A 2023 survey by the American Heartworm Society found that 2.5 percent of dogs tested in the United States were positive for heartworm antigen, with state-level prevalence ranging from under 0.5 percent to over 7 percent. Even in high-prevalence areas, human cases remain vanishingly rare. The discrepancy between canine and human infection rates points to a powerful species barrier.

Globally, human pulmonary dirofilariasis is reported more frequently in Japan, Australia, and parts of Europe, but still at rates measured in single cases per million population per year. A 2019 review in Clinical Microbiology Reviews noted that fewer than 1,500 human cases had been documented worldwide since the parasite was first identified in humans in 1940. The case fatality rate is essentially zero for pulmonary dirofilariasis, though the nodules it produces often require surgery to rule out malignancy.

The comparison is stark. A dog living in a heartworm-endemic region has a meaningful risk of infection, especially if not on preventives. A human living in the same household has a risk so low that it approaches background noise. The same mosquito population that infects dogs does bite humans, but the parasite fails at multiple checkpoints in the human body.

The rare human cases: what actually happens

When a mosquito carrying infective Dirofilaria immitis larvae bites a human, the larvae enter the skin. Most die locally, causing no symptoms. In the rare instances when a larva survives and migrates, it typically lodges in a small pulmonary artery. There, it cannot mature into an adult. Instead, it dies and triggers an inflammatory response that walls off the worm, forming a granuloma. Over weeks to months, this granuloma calcifies and appears on chest imaging as a coin lesion, usually 1 to 3 centimeters in diameter.

Most human patients have no symptoms. When symptoms occur, they are mild and nonspecific: a transient cough, chest discomfort, or low-grade fever. Eosinophilia is present in a minority of cases. Because the lesion mimics lung cancer on X-ray or CT scan, many patients undergo surgical biopsy or resection to rule out malignancy. The diagnosis is often made only after the pathology report identifies a necrotic filarial worm.

The time course from mosquito bite to nodule detection is not precisely established in humans, but extrapolation from animal models suggests several months. The worm does not produce microfilariae in humans, so there is no ongoing infection. There is no adult worm in the heart, no blockage of pulmonary arteries, no heart failure. This is a critical distinction. Human dirofilariasis is a localized, self-limiting granulomatous disease in almost all cases, not a systemic infection.

A different parasite, Dirofilaria repens, causes subcutaneous nodules in humans and is more common in parts of Europe and Asia. That species is transmitted by different mosquito vectors and is not the same organism that causes canine heartworm disease. Confusion between the two is common in popular accounts, but only Dirofilaria immitis is the dog heartworm, and its human manifestation is pulmonary, not subcutaneous.

Timeline: from mosquito bite to clinical outcome in humans

This timeline is derived from case reports and animal models, not from controlled human studies, which would be unethical and unnecessary given the rarity of the event. The key point is that the human host is a dead end. The parasite cannot reproduce, cannot spread to other humans, and cannot establish a chronic infection.

Variations and edge cases: who is at slightly higher risk?

The people at highest risk are those who spend extended time outdoors in heartworm-endemic regions with high mosquito densities. Outdoor workers, hunters, and residents of the southeastern United States face more mosquito bites per year, which statistically increases the chance of encountering an infective mosquito. But even among this group, documented cases are rare enough to be reportable in medical literature.

Immunocompromised individuals represent a theoretical concern. A person with a weakened immune system might be less able to kill larvae at the skin entry point, potentially allowing more larvae to migrate. However, the literature does not show a clear signal of increased human dirofilariasis in HIV-positive or transplant patients. The species barrier is robust and not primarily immune-mediated.

Children may be at slightly higher risk because they spend more time outdoors and may be less diligent about mosquito repellent. But pediatric cases are exceedingly rare. A 2021 review found fewer than 10 documented pediatric cases of pulmonary dirofilariasis worldwide in the prior two decades.

A more consequential edge case is the dog with a high microfilarial burden living in a household with poor mosquito control. The risk to humans is still minuscule, but the number of infective mosquitoes around that dog could be higher. This does not change the recommendation for humans, but it reinforces the importance of mosquito control and canine preventive treatment.

Common misconceptions about heartworms and humans

The most persistent misconception is that heartworms are contagious between pets and people. They are not. Heartworm is a vector-borne disease, not a contagious one. You cannot catch it from your dog's breath, saliva, blood, or feces. You cannot catch it by sleeping in the same bed. You cannot catch it by cleaning a wound or handling a heartworm-positive dog.

A second misconception is that a positive heartworm test in a dog means the family needs testing. Human testing is not recommended for asymptomatic household members of heartworm-positive dogs. There is no routine blood test for human dirofilariasis, and the diagnosis is usually made incidentally on imaging. Testing humans without symptoms would produce anxiety and unnecessary procedures without improving outcomes.

A third misconception is that human heartworm infection requires treatment. In almost all cases, the granuloma is self-limited and requires no intervention. Surgical resection is sometimes performed when malignancy cannot be excluded, but the surgery is diagnostic rather than therapeutic. There is no antiparasitic drug approved for human pulmonary dirofilariasis, and none is needed.

A fourth misconception is that heartworm preventives for dogs protect humans. They do not directly protect humans, but they do reduce the number of infected dogs, which reduces the pool of microfilariae available to mosquitoes. This herd effect lowers human exposure over time. It is a secondary benefit, not a primary rationale for canine preventive care.

What to actually do: practical steps for dog owners and households

If your dog tests positive for heartworms, the first action is to begin treatment under veterinary supervision. The American Heartworm Society recommends a three-dose melarsomine protocol for most dogs, along with doxycycline to eliminate Wolbachia bacteria that the worms depend on. This treatment reduces the microfilarial burden and improves the dog's prognosis.

The second action is to address mosquito exposure. Eliminate standing water around the home, use screens on windows, and apply pet-safe mosquito repellents if recommended by your veterinarian. These measures reduce the number of mosquitoes biting the dog and, incidentally, the humans in the household.

The third action is to keep the dog on year-round heartworm preventive after treatment. Reinfection is possible if the dog remains in an endemic area. The same preventive that protects the dog also reduces the reservoir of infection in the community.

The fourth action, for humans, is nothing specific. If a household member develops unexplained respiratory symptoms or a lung nodule is found on imaging, mention the dog's heartworm status to the physician. This is a low-probability scenario, but it is the only situation in which the information is clinically relevant.

Red-flag warnings for human household members:

• A new lung nodule on imaging in a person living with a heartworm-positive dog warrants mentioning the exposure to the radiologist or physician.
• Eosinophilia combined with a new pulmonary lesion should prompt consideration of parasitic causes, including dirofilariasis.
• Never assume a lung nodule in a dog owner is heartworm-related without biopsy; malignancy is far more common.
• Do not request human heartworm testing without a specific clinical reason; no standard test exists.
• Do not delay canine treatment out of fear of human transmission; the risk to humans is negligible and the risk to the dog is high.

Limitations of the evidence and what remains uncertain

The true incidence of human dirofilariasis is unknown because most cases are asymptomatic and never diagnosed. Seroprevalence studies using antibody tests have suggested that exposure may be more common than clinical case counts imply, but those tests cross-react with other filarial parasites and are not reliable for individual diagnosis. The 56 CDC-documented cases likely represent the tip of a much larger iceberg of subclinical exposures that never produce a detectable nodule.

The mechanism by which the human immune system kills most larvae is not fully characterized. Animal models show that complement and eosinophils play a role, but the precise checkpoint that stops larval migration in humans is not defined. This is an area of active research, though funding is limited given the rarity of human disease.

The role of climate change in altering human dirofilariasis risk is speculative. Warmer temperatures expand mosquito ranges and shorten the developmental period of larvae inside the mosquito, which could increase infectivity rates. But the species barrier remains the dominant factor, and no modeling studies predict a meaningful increase in human cases in the next century.

The relationship between Dirofilaria immitis and lung cancer is coincidental. There is no evidence that the granuloma predisposes to malignancy. The confusion arises because both produce coin lesions, and the workup for one often uncovers the other. This is a reminder that diagnostic uncertainty, not parasitic danger, drives most human interventions in these cases.

What is established is that canine heartworm is a serious disease for dogs, that human infection is a rare dead-end event, and that the two facts are connected by mosquito ecology rather than by contact. The fear of catching heartworms from a dog is understandable but misplaced. The dog is not the danger. The mosquito is the vector, and the human is almost never the host.